Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Kytopen develops genome engineering platforms that enable cell therapy research and manufacturing.
March Biosciences is a clinical-stage cell therapy company that develops CAR-T cell strategies to address hematological cancers.
Fathom Therapeutics focuses on drug design by harnessing biomolecular motion to develop therapeutics that can reprogram protein function.
Pheast Therapeutics develops checkpoint therapies to harness the innate immune system.
Neomorph develops protein degradation therapies targeting diseases not addressed by conventional treatments.
Function Oncology is a precision medicine company advancing a CRISPR-powered personalized functional genomics platform.
QurAlis is a biotechnology company that creates precision medicine solutions to cure ALS and FTD.
Ring Therapeutics is a gene therapy company focused on discovering and developing programmable genetic medicines.
Reinventing drug development from the ground up to make safe, effective oligonucleotide-based medicines possible on demand.
Umaro Foods uses green chemistry to unlock value-added ingredients and chemicals from seaweed
Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer.
Vesigen Therapeutics is a biotechnology company that develops groundbreaking therapeutic products.
IgGenix is a biotechnology company.
Applied Therapeutics uses drug-development approach to target molecules and pathways that has roles in fatal or debilitating diseases.
Paratus Sciences is dedicated to advancing human health and health security by comprehending the biology of bats.
Cyrus Biotechnology is a developer of Rosetta software platform that solves drug discovery problems.
Acrigen Biosciences is dedicated to making gene editing safe.
Blacksmith Medicines developing medicines targeting metal-dependent enzymes found in human physiology.
Tr1x is a biotechnology company developing novel cellular immunotherapies for patients with autoimmune and inflammatory diseases.
AeroRx Therapeutics is a biopharmaceutical company that developing proprietary, combination products.
Dualitas Therapeutics is leading the way in bispecific antibody treatments for inflammatory and immunological (I&I) disorders
Leal Therapeutics develops novel therapeutics for patients.
GeneCentric Therapeutics develops and commercializes molecular diagnostic tests for oncologists and patients.
Remedy Plan is a pre-clinical cancer therapeutics company developing first-in-class small molecule drugs that differentiate cancer cells.
Alexandria Venture Investments has invested in 186 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Alexandria Venture Investments's top investment sectors include Biotechnology, Health Care, Therapeutics, Life Science, Medical. The firm invests across 20 different industry categories.
Among tracked funding rounds, Affini-T Therapeutics received $175.0M in a Venture - Series Unknown round. Alexandria Venture Investments's total known invested capital is $7.4B.
Alexandria Venture Investments's average investment size is $50.9M across its portfolio of 186 companies.
Recent Alexandria Venture Investments portfolio additions include Kytopen, March Biosciences, Fathom Therapeutics, Pheast Therapeutics, Neomorph. These companies were founded in 2020 or later.